Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

An injection pen of Zepbound, Eli Lilly’s weight-loss drug ... week reported a rare $1.5 billion sales miss for its ...

Eli Lilly shares slid in premarket trading after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inven ...

Eli Lilly had a bad quarter, with sales of GLP-1 drugs Mounjaro and Zepbound missing analyst estimates. The disappointment led to a [15% plunge in Lilly’s shares]( ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...

However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...

(Reuters) -Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...